Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 3/20 | 0.34 |
| ▸ | CDK8 | P49336 | 3/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553102 | 0.91 | ALDH1A1 (0.37) | SMN1; SMN2PIM3 | |
| SCHEMBL4553100 | 0.91 | ALDH1A1 (0.37) | SMN1; SMN2PIM3 | |
| SCHEMBL966849 | 0.90 | TDP1 (0.36) | POLBSMN1; SMN2CCNCCDK8PHGDH | |
| SCHEMBL966848 | 0.90 | TDP1 (0.36) | POLBSMN1; SMN2CCNCCDK8PHGDH | |
| SCHEMBL962379 | 0.89 | PIM3 (0.39) | POLBCCNCCDK8PHGDHPDE4B | |
| SCHEMBL964594 | 0.86 | CCNC (0.35) | POLBSMN1; SMN2CCNCCDK8PHGDH | |
| SCHEMBL963541 | 0.85 | CYP1A2 (0.43) | CCNCCDK8PDE4BCYP1A2CYP3A4 | |
| SCHEMBL966841 | 0.85 | CCNC (0.38) | CCNCCDK8CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL966599 | 0.85 | ABL1 (0.37) | POLBSMN1; SMN2CCNCCDK8PHGDH | |
| SCHEMBL965490 | 0.85 | PIM3 (0.32) | POLBSMN1; SMN2PHGDHPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | POLB 1580/4885SMN1; SMN2 4710/4885CCNC 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.